Calcium channel blockers in diabetic subjects: Innocent at last?

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 12, Issue 4, 1999, Pages 249-251

  Zoccali, C ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; ISRADIPINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA ANALYSIS; DIABETES MELLITUS; EDITORIAL; ERROR; HEART DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION;

EID: 0032716157     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (15)

1. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension: Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J. Hum. Hypertens. 11: 331-342, 1997.
2. Stelfox H.T., Chua G., O'Rourke K., Detsky A.S.: Conflict of interest in the debate over calcium-channel antagonists. N. Engl. J. Med. 338: 101-106, 1998.
3. Borhani N.O., Mercuri M., Borhani P.A., Buckalew V.M., Carr A.A.C.T., Kappagoda T., et al: Final outcome results of the multicenter Isradipine diuretic atherosclerosis study (MIDAS). A randomised controlled trial. J.A.M.A. 276: 785-791, 1996.
4. Tatti P., Pahor M., Byington R.P., DiMauro P., Guarisco R., Strollo F.: Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non- insulin dependent diabetes mellitus (NIDDM). Circulation 96 (Suppl. 1): 1.764, 1997 (Abstract).
5. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non- insulin-dependent diabetes and hypertension. N. Engl. J. Med. 338: 645-652, 1998.
6. Unsigned editorial: Calcium-channel blockers: managing uncertainty. Lancet 348: 487, 1996.
7. Byington R.P., Craven T., Furberg C.D., Pabor M.: Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 350: 1075-1076, 1997.
8. Pahor M., Psaty B., Furberg C.D.: Treatment of hypertensive patients with diabetes. Lancet 351: 689, 1998.
9. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F.E., Motolese M., Ponticelli C., Ritz E., Zucchelli P.: Effect of the Angiotensin-Converting-Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. N. Engl. J. Med. 334: 939-945, 1996.
10. Stanton A.V.: Calcium channel blockers. B.M.J. 316: 1471-1473, 1998.
11. Muldoon M.F., Manuck S.B., Mathews K.A.: Mortality experience in cholesterol-reduction trial. N. Engl. J. Med. 324: 922-923, 1991.
12. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994.
13. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 333: 1301-1307, 1995.
14. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335: 1001-1009, 1996.
15. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755-1762, 1998.